While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. That said, here are three profitable companies that don’t make the cut and some better opportunities instead.
Q2 Holdings (QTWO)
Trailing 12-Month GAAP Operating Margin: 5%
With a platform powering digital services for approximately 25 million account holders across America, Q2 Holdings (NYSE: QTWO) provides cloud-based digital solutions that help financial institutions, fintechs, and alternative finance companies deliver modern banking experiences to their customers.
Why Are We Wary of QTWO?
- Underwhelming ARR growth of 11.2% over the last year suggests the company faced challenges in acquiring and retaining long-term customers
- Estimated sales growth of 10.3% for the next 12 months implies demand will slow from its two-year trend
- Gross margin of 54.1% is way below its competitors, leaving less money to invest in areas like marketing and R&D
Q2 Holdings is trading at $51.27 per share, or 4.1x forward price-to-sales. To fully understand why you should be careful with QTWO, check out our full research report (it’s free).
ANI Pharmaceuticals (ANIP)
Trailing 12-Month GAAP Operating Margin: 12.6%
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Are We Cautious About ANIP?
- Modest revenue base of $883.4 million gives it less fixed cost leverage and fewer distribution channels than larger companies
- Efficiency has decreased over the last two years as its adjusted operating margin fell by 1.6 percentage points
- Negative returns on capital show management lost money while trying to expand the business
ANI Pharmaceuticals’s stock price of $75.98 implies a valuation ratio of 8.3x forward P/E. Dive into our free research report to see why there are better opportunities than ANIP.
BNY (BK)
Trailing 12-Month GAAP Operating Margin: 36.1%
Tracing its roots back to 1784 when it was founded by Alexander Hamilton, BNY (NYSE: BK) is a global financial institution that provides asset servicing, wealth management, and investment services to institutions, corporations, and high-net-worth individuals.
Why Is BK Not Exciting?
- Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 4.7% for the last five years
- Annual tangible book value per share growth of 3.2% over the last five years lagged behind its financials peers as its large balance sheet made it difficult to generate incremental capital growth
- Below-average return on equity indicates management struggled to find compelling investment opportunities
At $115.43 per share, BNY trades at 13.8x forward P/E. Check out our free in-depth research report to learn more about why BK doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
